Literature DB >> 9698235

Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.

J van Asperen1, O van Tellingen, J H Beijnen.   

Abstract

A sensitive and selective reversed-phase high-performance liquid chromatographic method for the quantification of doxorubicin and its metabolites doxorubicinol, 7-deoxydoxorubicinone and 7-deoxydoxorubicinolone was developed and validated for a variety of murine specimens. Daunorubicin was used as internal standard. Sample pretreatment involved liquid-liquid extraction of 200 microl sample with 1 ml of chloroform-1-propanol (4:1, v/v). Chromatographic separation was achieved isocratically on a LiChrosorb RP-8 analytical column at ambient temperature. The mobile phase consisted of acidified water (pH 2.05)-acetonitrile-tetrahydrofuran (80:30:1, v/v/v). The column effluent was monitored fluorimetrically at an excitation wavelength of 460 nm and an emission wavelength of 550 nm. The lower limits of quantitation were in the range 1.8-2.4 nM. Spiked murine specimens and samples from treated mice were subjected to stability studies. The results demonstrated the importance of validation in all relevant specimens, since the accuracy and precision were highly matrix-dependent. Accuracies and precisions of measured drug concentrations in liver, spleen, muscle, gastrointestinal tissues, diluted bile, feces and urine were lower than in the other matrices. Doxorubicin was unstable in diluted bile, but not in the other specimens. The method is suitable for studying the pharmacokinetics of doxorubicin and its metabolites in mice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9698235     DOI: 10.1016/s0378-4347(98)00165-0

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  11 in total

1.  Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy.

Authors:  Robert D Arnold; Jeanine E Slack; Robert M Straubinger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-09-05       Impact factor: 3.205

Review 2.  Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.

Authors:  Rachel E Nicoletto; Clyde M Ofner
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-12       Impact factor: 3.333

3.  Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

Authors:  Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nikolas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Régine Féty; Ernst de Bruijn; Georg Hempel; Mats Karlsson; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin.

Authors:  N Gyémánt; H Engi; Z Schelz; I Szatmári; D Tóth; F Fülöp; J Molnár; P A M de Witte
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

5.  Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.

Authors:  J van Asperen; O van Tellingen; F Tijssen; A H Schinkel; J H Beijnen
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

6.  A Simple and Sensitive HPLC Method for Fluorescence Quantitation of Doxorubicin in Micro-volume Plasma: Applications to Pharmacokinetic Studies in Rats.

Authors:  Marjan Daeihamed; Azadeh Haeri; Simin Dadashzadeh
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

7.  Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).

Authors:  Pieter J Gaillard; Chantal C M Appeldoorn; Rick Dorland; Joan van Kregten; Francesca Manca; Danielle J Vugts; Bert Windhorst; Guus A M S van Dongen; Helga E de Vries; David Maussang; Olaf van Tellingen
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

8.  Uncoupling DNA damage from chromatin damage to detoxify doxorubicin.

Authors:  Xiaohang Qiao; Sabina Y van der Zanden; Dennis P A Wander; Daniel M Borràs; Ji-Ying Song; Xiaoyang Li; Suzanne van Duikeren; Noortje van Gils; Arjo Rutten; Tessa van Herwaarden; Olaf van Tellingen; Elisa Giacomelli; Milena Bellin; Valeria Orlova; Leon G J Tertoolen; Sophie Gerhardt; Jimmy J Akkermans; Jeroen M Bakker; Charlotte L Zuur; Baoxu Pang; Anke M Smits; Christine L Mummery; Linda Smit; Ramon Arens; Junmin Li; Hermen S Overkleeft; Jacques Neefjes
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-17       Impact factor: 11.205

9.  PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line.

Authors:  Stefan Harmsen; I Meijerman; C L Febus; R F Maas-Bakker; J H Beijnen; J H M Schellens
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-30       Impact factor: 3.333

10.  Pharmacokinetics of a liposomal formulation of doxorubicin in rats.

Authors:  Zongyu Liu; Ye Bi; Yating Sun; Fei Hao; Jiahui Lu; Qingfan Meng; Robert J Lee; Yaping Tian; Jing Xie
Journal:  Saudi Pharm J       Date:  2017-05-13       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.